Načítá se...
EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers
BACKGROUND: A critical and challenging process in immunotherapy is to identify cancer patients who could benefit from immune checkpoint inhibitors (ICIs). Exploration of predictive biomarkers could help to maximize the clinical benefits. Eph receptors have been shown to play essential roles in tumor...
Uloženo v:
| Vydáno v: | BMC Med |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7852135/ https://ncbi.nlm.nih.gov/pubmed/33526018 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-020-01899-x |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|